Home  /   Products  /   Musculoskeletal system  /   Chondroitin sulfate (Mucosat) solution for intramuscular and intraarticular administration 100 mg/ml 1 ml – [10 ampoules]
Chondroitin sulfate (Mucosat) solution for intramuscular and intraarticular administration 100 mg/ml 1 ml - [10 ampoules]

Chondroitin sulfate (Mucosat) solution for intramuscular and intraarticular administration 100 mg/ml 1 ml – [10 ampoules]

$54.65

A drug that regulates the metabolism in cartilage tissue

SKU: 62152 Category:

Description

Mucosat Pharmacodynamics
The drug has chondroprotective, stimulates the regeneration of cartilage tissue, and anti-inflammatory action. It participates in the construction of the basic substance of cartilage and bone tissue, improves phosphorus – calcium metabolism in the cartilage tissue, inhibits enzymes that disrupt the structure and function of articular cartilage, inhibits the process of degeneration of cartilage. Stimulates the synthesis of proteoglycans, normalizes the metabolism of hyaline cartilage, promotes the regeneration of cartilage surfaces and the joint capsule. It prevents compression of connective tissue, increases synovial fluid production and mobility of affected joints, reduces associated inflammation and pain, and helps reduce the need for NSAIDs.
In degenerative changes of cartilage tissue is a means of substitution therapy.
Positive effect is observed in 2-3 weeks after the beginning of the drug administration. The therapeutic effect persists for a long time (3-6 months) after the end of treatment.
Having structural similarity with heparin, it can potentially prevent the formation of fibrin clots in the synovial and subchondral microcirculatory channel.

 

Indications
Degenerative-dystrophic diseases of the joints and spine:
– osteoarthritis of the peripheral joints;
– Intervertebral osteochondrosis and osteoarthritis.
To accelerate the formation of the bone callus for fractures

 

Contraindications
– Hypersensitivity to chondroitin sulfate or any excipient of the drug;
– Bleeding and tendency to bleeding;
– thrombophlebitis;
– in case of intraarticular injection: the presence of active inflammatory or infectious processes in the joint, the presence of active skin disease or skin infection in the area of the intended injection;
– children under 18 years of age, pregnancy and breastfeeding (efficacy and safety have not been established).

 

Dosage and administration

 

  • Mucosat® is intramuscularly injected by 100 mg (1 ml) every other day.
  • If tolerated, the dose is increased to 200 mg (2 ml), starting with the fourth injection. The course of treatment is 25-30 injections. If necessary, there may be repeated courses in 6 months.
  • For the formation of the bone callus the course of treatment is 3-4 weeks (10-14 injections a day).
  • With osteoarthritis of large joints it is possible to combine intraarticular and intramuscular injection methods. Up to 5 intraarticular injections of 200 mg with 3 days’ interval between injections and 16 intramuscular injections of 200 mg with 1 day interval between injections (every other day).
  • Intra-articular injection of the drug is carried out under aseptic conditions by a specialist trained in the technique of intra-articular injection. Depending on the size of the joint, up to 2 ml of Mucosat® can be injected into the joint cavity.
  • After intraarticular injection of the drug the puncture site is lubricated with an alcohol napkin and a bactericidal plaster is applied.

Related products